Related coverage linked through entity extraction aliases.
Apr 28, 2026
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Apr 24, 2026
Two retrospective studies in type 2 diabetes patients with unruptured intracranial aneurysms linked GLP-1RAs to lower non-traumatic subarachnoid haemorrhage risk. One study also showed lower all-cause mortality over five years.
Mar 05, 2026
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Mar 03, 2026
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Mar 03, 2026
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Feb 18, 2026
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 18, 2026
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Feb 14, 2026
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
